Bio-Rad Laboratories, Inc. logo
Bio-Rad Laboratories, Inc. (BIO)
Compare

Bio-Rad Laboratories, Inc. (BIO) EV/EBITDA Ratio: 256.71x

Is Bio-Rad Laboratories, Inc.’s EV/EBITDA ratio high or low?

Bio-Rad Laboratories, Inc.'s EV/EBITDA ratio of 256.71x is 316% above its 5-year average of 61.74x, near the high end of its 5-year range (1.50x–273.11x).

The EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO) is 256.71x as of Tuesday, June 9, 2026. It is above its 12-month average by 389.48% (52.45x).

BIO EV/EBITDA Ratio Chart

BIO EV/EBITDA Ratio
262.68x+123.54% 1Y
Zoom

BIO Average EV/EBITDA Ratio Chart

BIO Current vs Average EV/EBITDA Ratio Chart

BIO EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

256.71x

EV/EBITDA RATIO AVG TTM

52.45x

EV/EBITDA RATIO AVG 3Y

101.26x

EV/EBITDA RATIO AVG 5Y

61.74x

EV/EBITDA RATIO AVG 10Y

38.62x

EV/EBITDA RATIO AVG 15Y

29.18x

EV/EBITDA RATIO AVG 20Y

24.43x

CURRENT VS TTM AVG

+389.48%

CURRENT VS 3Y AVG

+153.52%

CURRENT VS 5Y AVG

+315.78%

CURRENT VS 10Y AVG

+564.66%

CURRENT VS 15Y AVG

+779.86%

CURRENT VS 20Y AVG

+950.71%

BIO Competitors' EV/EBITDA Ratio

NAMEMARKET CAPEV/EBITDA RATIOTTM3Y5Y
Bio-Rad Laboratories, Inc. (BIO)256.71x52.45x101.26x61.74x
Charles River Laboratories International, Inc. (CRL)$9.14B15.12x19.05x15.54x17.41x
Hims & Hers Health, Inc. (HIMS)$6.46B75.39x67.25x332.85x332.85x
Align Technology, Inc. (ALGN)$12.76B14.60x13.92x20.43x25.96x
Hologic, Inc. (HOLX)$16.97B17.28x15.01x15.35x12.41x
Moderna, Inc. (MRNA)$18.94B12.76x9.19x17.17x19.33x
BioNTech SE (BNTX)$21.87B206.26x270.12x198.48x120.89x
Mettler-Toledo International Inc. (MTD)$23.50B20.79x23.57x23.88x26.51x
Waters Corporation (WAT)$24.19B38.50x21.53x21.21x21.44x
Veeva Systems Inc. (VEEV)$27.37B26.02x43.41x56.96x62.43x

EV/EBITDA vs. its own history

At 256.7, EV/EBITDA is richer than usual — richer than 100% of its 20-year range.

20-year low

1.5

median

10.2

20-year high

273.1

cheaperricher

Understanding EV/EBITDA

Enterprise Value (EV) = Market Cap + Total Debt - Cash

EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization

EV/EBITDA is commonly used for comparing companies because:

  • It accounts for debt levels (capital structure neutral)
  • It removes effects of different depreciation policies
  • It can be compared across countries with different tax rates
  • It can remain available when net income is negative, if EBITDA is positive

Bio-Rad Laboratories, Inc. EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Bio-Rad Laboratories, Inc. EV/EBITDA Ratio FAQ

What is the EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
The EV/EBITDA ratio for BIO stock is 256.71x.
Is Bio-Rad Laboratories, Inc.'s EV/EBITDA ratio high or low?
Bio-Rad Laboratories, Inc.'s EV/EBITDA ratio of 256.71x is 316% above its 5-year average of 61.74x, near the high end of its 5-year range (1.50x–273.11x).
What is the TTM average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
The TTM average EV/EBITDA ratio for BIO stock is 52.45x.
What is the 3Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 3Y average EV/EBITDA ratio for BIO stock is 101.26x.
What is the 5Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 5Y average EV/EBITDA ratio for BIO stock is 61.74x.
What is the 10Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 10Y average EV/EBITDA ratio for BIO stock is 38.62x.
What is the 15Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 15Y average EV/EBITDA ratio for BIO stock is 29.18x.
What is the 20Y average EV/EBITDA ratio for Bio-Rad Laboratories, Inc. (BIO)?
The 20Y average EV/EBITDA ratio for BIO stock is 24.43x.

Bio-Rad Laboratories, Inc. EV/EBITDA Ratio History

DATEEV/EBITDA RATIO
2026-06-03262.68x
2026-06-02263.69x
2026-06-01263.17x
2026-05-29268.64x
2026-05-28273.11x
2026-05-27263.03x
2026-05-26256.50x
2026-05-22249.36x
2026-05-21248.58x
2026-05-20249.45x
2026-05-19244.15x
2026-05-18244.75x
2026-05-15218.03x
2026-05-14217.05x
2026-05-13214.90x
2026-05-12213.50x
2026-05-11215.12x
2026-05-08223.32x
2026-05-07225.66x
2026-05-06226.98x
2026-05-05225.50x
2026-05-04226.08x
2026-05-01225.06x
2026-04-30243.42x
2026-04-299.97x
2026-04-2810.10x
2026-04-2710.36x
2026-04-2410.38x
2026-04-2310.17x
2026-04-2210.79x
2026-04-2110.95x
2026-04-2010.87x
2026-04-1710.73x
2026-04-1610.48x
2026-04-1510.64x
2026-04-1410.52x
2026-04-1310.39x
2026-04-1010.10x
2026-04-0910.05x
2026-04-0810.16x
2026-04-0710.06x
2026-04-0610.09x
2026-04-0210.13x
2026-04-0110.07x
2026-03-3110.09x
2026-03-309.82x
2026-03-279.66x
2026-03-2610.02x
2026-03-259.92x
2026-03-249.87x
2026-03-239.65x
2026-03-209.63x
2026-03-199.65x
2026-03-189.74x
2026-03-179.79x
2026-03-169.53x
2026-03-139.58x
2026-03-129.55x
2026-03-119.80x
2026-03-109.74x
2026-03-099.85x
2026-03-069.80x
2026-03-0510.10x
2026-03-0410.28x
2026-03-0310.13x
2026-03-0210.11x
2026-02-2710.08x
2026-02-269.97x
2026-02-259.80x
2026-02-249.77x
2026-02-239.75x
2026-02-209.85x
2026-02-199.87x
2026-02-189.83x
2026-02-179.64x
2026-02-139.38x
2026-02-1210.52x
2026-02-1113.17x
2026-02-1013.41x
2026-02-0913.21x
2026-02-0613.47x
2026-02-0513.40x
2026-02-0413.65x
2026-02-0313.37x
2026-02-0213.31x
2026-01-3013.17x
2026-01-2913.21x
2026-01-2813.41x
2026-01-2713.32x
2026-01-2613.39x
2026-01-2313.28x
2026-01-2213.62x
2026-01-2113.87x
2026-01-2013.92x
2026-01-1613.95x
2026-01-1514.29x
2026-01-1414.14x
2026-01-1314.30x
2026-01-1214.33x
2026-01-0914.36x
2026-01-0814.17x
2026-01-0714.37x
2026-01-0614.43x
2026-01-0514.30x
2026-01-0213.62x
2025-12-3113.53x
2025-12-3013.59x
2025-12-2913.56x
2025-12-2613.57x
2025-12-2413.48x
2025-12-2313.46x
2025-12-2213.61x
2025-12-1913.48x
2025-12-1813.41x
2025-12-1713.47x
2025-12-1613.50x
2025-12-1513.73x
2025-12-1213.74x
2025-12-1113.97x
2025-12-1014.01x
2025-12-0913.73x
2025-12-0813.75x
2025-12-0514.12x
2025-12-0414.21x
2025-12-0314.22x
2025-12-0214.15x
2025-12-0114.27x
2025-11-2814.40x
2025-11-2614.49x
2025-11-2514.69x
2025-11-2414.31x
2025-11-2114.08x
2025-11-2013.56x
2025-11-1913.61x
2025-11-1813.72x
2025-11-1713.58x
2025-11-1413.94x
2025-11-1314.09x
2025-11-1214.50x
2025-11-1113.94x
2025-11-1013.71x
2025-11-0713.64x
2025-11-0613.68x
2025-11-0513.81x
2025-11-0413.85x
2025-11-0313.87x
2025-10-3114.19x
2025-10-3013.60x
2025-10-2914.19x
2025-10-2814.62x
2025-10-2714.85x
2025-10-2414.99x
2025-10-2314.95x
2025-10-2214.76x
2025-10-2114.66x
2025-10-2014.28x
2025-10-1713.81x
2025-10-1613.91x
2025-10-1513.65x
2025-10-1413.62x
2025-10-1313.56x
2025-10-1013.32x
2025-10-0913.44x
2025-10-0813.53x
2025-10-0713.28x
2025-10-0613.78x
2025-10-0313.63x
2025-10-0213.19x
2025-10-0113.33x
2025-09-3012.64x
2025-09-2912.23x
2025-09-2612.28x
2025-09-2512.24x
2025-09-2412.49x
2025-09-2312.70x
2025-09-2212.76x
2025-09-1912.78x
2025-09-1812.88x
2025-09-1712.63x
2025-09-1612.71x
2025-09-1512.63x
2025-09-1212.64x
2025-09-1112.86x
2025-09-1012.50x
2025-09-0912.86x
2025-09-0813.03x
2025-09-0513.23x
2025-09-0413.00x
2025-09-0312.94x
2025-09-0213.05x
2025-08-2913.33x
2025-08-2813.16x
2025-08-2713.13x
2025-08-2613.28x
2025-08-2513.31x
2025-08-2213.57x
2025-08-2112.82x
2025-08-2012.95x
2025-08-1912.95x
2025-08-1812.81x
2025-08-1512.85x
2025-08-1412.91x
2025-08-1312.91x
2025-08-1212.41x
2025-08-1112.01x
2025-08-0812.00x
2025-08-0712.04x
2025-08-0612.00x
2025-08-0512.31x
2025-08-0412.49x
2025-08-0112.80x
2025-07-3111.11x
2025-07-30131.22x
2025-07-29132.39x
2025-07-28132.68x
2025-07-25137.77x
2025-07-24136.78x
2025-07-23134.46x
2025-07-22129.08x
2025-07-21128.51x
2025-07-18129.51x
2025-07-17131.02x
2025-07-16129.91x
2025-07-15129.95x
2025-07-14131.56x
2025-07-11134.42x
2025-07-10135.77x
2025-07-09132.61x
2025-07-08131.52x
2025-07-07129.82x
2025-07-03131.91x
2025-07-02131.48x
2025-07-01130.25x
2025-06-30127.15x
2025-06-27128.38x
2025-06-26128.15x
2025-06-25126.99x
2025-06-24125.57x
2025-06-23124.46x
2025-06-20125.02x
2025-06-18122.82x
2025-06-17122.10x
2025-06-16122.68x
2025-06-13120.46x
2025-06-12123.02x
2025-06-11121.98x
2025-06-10122.13x
2025-06-09119.83x
2025-06-06116.98x
2025-06-05116.93x
2025-06-04118.20x
2025-06-03117.51x
2025-06-02115.65x
2025-05-30120.47x
2025-05-29120.78x
2025-05-28121.50x
2025-05-27122.06x
2025-05-23119.00x
2025-05-22120.56x
2025-05-21120.95x

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

Hercules, CA
7,700 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Norman D. Schwartz